Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma : a multicenter trial
Stage III and IV epithelial ovarian cancer patients were prospectively randomized to receive eight courses of 60 mg/m2 of cisplatin plus either 75 mg/m2 of epirubicin (62 patients) or 60 mg/m2 of doxorubicin (54 patients). Clinical response rates for cisplatin/epirubicin of 42% [15% complete respons...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1992-04, Vol.15 (2), p.129-134 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 134 |
|---|---|
| container_issue | 2 |
| container_start_page | 129 |
| container_title | American journal of clinical oncology |
| container_volume | 15 |
| creator | HOMESLEY, H. D HARRY, D. S O'TOOLE, R. V HOOGSTRATEN, B FRANKLIN, E. W CAVANAGH, D NAHHAS, W. A SMITH, J. J LOVELACE, J. V |
| description | Stage III and IV epithelial ovarian cancer patients were prospectively randomized to receive eight courses of 60 mg/m2 of cisplatin plus either 75 mg/m2 of epirubicin (62 patients) or 60 mg/m2 of doxorubicin (54 patients). Clinical response rates for cisplatin/epirubicin of 42% [15% complete response (CR) and 27% partial response (PR)] and for cisplatin/doxorubicin of 55% (24% CR and 31% PR) were not statistically different (p = 0.14). The negative second look rate was 35% (10/29) for cisplatin/doxorubicin and 17% (5/30) for cisplatin/epirubicin (p = 0.12). The progression-free interval for cisplatin/epirubicin (13 months) was not statistically different (p = 0.09) from that for cisplatin/doxorubicin (19 months). The median survivals for cisplatin/epirubicin (756 days) and cisplatin/doxorubicin (739 days) were similar (p = 0.70). Cardiotoxicity was greater for the cisplatin/doxorubicin group (p = 0.0003). With similar survival and less cardiotoxicity, the cisplatin/epirubicin regimen had the more favorable therapeutic index. |
| doi_str_mv | 10.1097/00000421-199204000-00007 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00000421_199204000_00007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1553900</sourcerecordid><originalsourceid>FETCH-LOGICAL-c284t-d7225ea566d4499f859085f2384fd13e538efec756ec28aea0dc7d9da4e1e7fc3</originalsourceid><addsrcrecordid>eNpFkElLxDAYhoMo4zj6E4QcvFazNE3rTQY3GBBEwVv5JgtG2qYk7aDe_OdmnMVcwvu9y-FBCFNySUklr8j65YxmtKoYyZPI1hd5gKZUcJnlgr8doilhUmZccnaMTmL8SAlREDlBEyoErwiZop9n6LRv3bfRWPm2h-Ci77C3WLnYNzC4DvfNGLHpXRiXTiXtA9b-0--kTRr0CjqVNlJseDeNgwb7VRqDDisIKeZbwNcYcDs2g1OmG0zAQ_KbU3RkoYnmbPvP0Ovd7cv8IVs83T_ObxaZYmU-ZFoyJgyIotB5XlW2FBUphWW8zK2m3AheGmuUFIVJBTBAtJK60pAbaqRVfIbKza4KPsZgbN0H10L4qimp11DrHdR6D_XvJFP1fFPtx2Vr9H9xQzH5F1sfooLGhsTCxX1MCEFKzvgvcAmCig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma : a multicenter trial</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>HOMESLEY, H. D ; HARRY, D. S ; O'TOOLE, R. V ; HOOGSTRATEN, B ; FRANKLIN, E. W ; CAVANAGH, D ; NAHHAS, W. A ; SMITH, J. J ; LOVELACE, J. V</creator><creatorcontrib>HOMESLEY, H. D ; HARRY, D. S ; O'TOOLE, R. V ; HOOGSTRATEN, B ; FRANKLIN, E. W ; CAVANAGH, D ; NAHHAS, W. A ; SMITH, J. J ; LOVELACE, J. V</creatorcontrib><description>Stage III and IV epithelial ovarian cancer patients were prospectively randomized to receive eight courses of 60 mg/m2 of cisplatin plus either 75 mg/m2 of epirubicin (62 patients) or 60 mg/m2 of doxorubicin (54 patients). Clinical response rates for cisplatin/epirubicin of 42% [15% complete response (CR) and 27% partial response (PR)] and for cisplatin/doxorubicin of 55% (24% CR and 31% PR) were not statistically different (p = 0.14). The negative second look rate was 35% (10/29) for cisplatin/doxorubicin and 17% (5/30) for cisplatin/epirubicin (p = 0.12). The progression-free interval for cisplatin/epirubicin (13 months) was not statistically different (p = 0.09) from that for cisplatin/doxorubicin (19 months). The median survivals for cisplatin/epirubicin (756 days) and cisplatin/doxorubicin (739 days) were similar (p = 0.70). Cardiotoxicity was greater for the cisplatin/doxorubicin group (p = 0.0003). With similar survival and less cardiotoxicity, the cisplatin/epirubicin regimen had the more favorable therapeutic index.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/00000421-199204000-00007</identifier><identifier>PMID: 1553900</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma - drug therapy ; Carcinoma - pathology ; Chemotherapy ; Cisplatin - administration & dosage ; Double-Blind Method ; Doxorubicin - administration & dosage ; Epirubicin - administration & dosage ; Female ; Humans ; Medical sciences ; Middle Aged ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Pharmacology. Drug treatments ; Prospective Studies ; Survival Analysis</subject><ispartof>American journal of clinical oncology, 1992-04, Vol.15 (2), p.129-134</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5550832$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1553900$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOMESLEY, H. D</creatorcontrib><creatorcontrib>HARRY, D. S</creatorcontrib><creatorcontrib>O'TOOLE, R. V</creatorcontrib><creatorcontrib>HOOGSTRATEN, B</creatorcontrib><creatorcontrib>FRANKLIN, E. W</creatorcontrib><creatorcontrib>CAVANAGH, D</creatorcontrib><creatorcontrib>NAHHAS, W. A</creatorcontrib><creatorcontrib>SMITH, J. J</creatorcontrib><creatorcontrib>LOVELACE, J. V</creatorcontrib><title>Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma : a multicenter trial</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>Stage III and IV epithelial ovarian cancer patients were prospectively randomized to receive eight courses of 60 mg/m2 of cisplatin plus either 75 mg/m2 of epirubicin (62 patients) or 60 mg/m2 of doxorubicin (54 patients). Clinical response rates for cisplatin/epirubicin of 42% [15% complete response (CR) and 27% partial response (PR)] and for cisplatin/doxorubicin of 55% (24% CR and 31% PR) were not statistically different (p = 0.14). The negative second look rate was 35% (10/29) for cisplatin/doxorubicin and 17% (5/30) for cisplatin/epirubicin (p = 0.12). The progression-free interval for cisplatin/epirubicin (13 months) was not statistically different (p = 0.09) from that for cisplatin/doxorubicin (19 months). The median survivals for cisplatin/epirubicin (756 days) and cisplatin/doxorubicin (739 days) were similar (p = 0.70). Cardiotoxicity was greater for the cisplatin/doxorubicin group (p = 0.0003). With similar survival and less cardiotoxicity, the cisplatin/epirubicin regimen had the more favorable therapeutic index.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - pathology</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Double-Blind Method</subject><subject>Doxorubicin - administration & dosage</subject><subject>Epirubicin - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Survival Analysis</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkElLxDAYhoMo4zj6E4QcvFazNE3rTQY3GBBEwVv5JgtG2qYk7aDe_OdmnMVcwvu9y-FBCFNySUklr8j65YxmtKoYyZPI1hd5gKZUcJnlgr8doilhUmZccnaMTmL8SAlREDlBEyoErwiZop9n6LRv3bfRWPm2h-Ci77C3WLnYNzC4DvfNGLHpXRiXTiXtA9b-0--kTRr0CjqVNlJseDeNgwb7VRqDDisIKeZbwNcYcDs2g1OmG0zAQ_KbU3RkoYnmbPvP0Ovd7cv8IVs83T_ObxaZYmU-ZFoyJgyIotB5XlW2FBUphWW8zK2m3AheGmuUFIVJBTBAtJK60pAbaqRVfIbKza4KPsZgbN0H10L4qimp11DrHdR6D_XvJFP1fFPtx2Vr9H9xQzH5F1sfooLGhsTCxX1MCEFKzvgvcAmCig</recordid><startdate>19920401</startdate><enddate>19920401</enddate><creator>HOMESLEY, H. D</creator><creator>HARRY, D. S</creator><creator>O'TOOLE, R. V</creator><creator>HOOGSTRATEN, B</creator><creator>FRANKLIN, E. W</creator><creator>CAVANAGH, D</creator><creator>NAHHAS, W. A</creator><creator>SMITH, J. J</creator><creator>LOVELACE, J. V</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920401</creationdate><title>Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma : a multicenter trial</title><author>HOMESLEY, H. D ; HARRY, D. S ; O'TOOLE, R. V ; HOOGSTRATEN, B ; FRANKLIN, E. W ; CAVANAGH, D ; NAHHAS, W. A ; SMITH, J. J ; LOVELACE, J. V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c284t-d7225ea566d4499f859085f2384fd13e538efec756ec28aea0dc7d9da4e1e7fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - pathology</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Double-Blind Method</topic><topic>Doxorubicin - administration & dosage</topic><topic>Epirubicin - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOMESLEY, H. D</creatorcontrib><creatorcontrib>HARRY, D. S</creatorcontrib><creatorcontrib>O'TOOLE, R. V</creatorcontrib><creatorcontrib>HOOGSTRATEN, B</creatorcontrib><creatorcontrib>FRANKLIN, E. W</creatorcontrib><creatorcontrib>CAVANAGH, D</creatorcontrib><creatorcontrib>NAHHAS, W. A</creatorcontrib><creatorcontrib>SMITH, J. J</creatorcontrib><creatorcontrib>LOVELACE, J. V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOMESLEY, H. D</au><au>HARRY, D. S</au><au>O'TOOLE, R. V</au><au>HOOGSTRATEN, B</au><au>FRANKLIN, E. W</au><au>CAVANAGH, D</au><au>NAHHAS, W. A</au><au>SMITH, J. J</au><au>LOVELACE, J. V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma : a multicenter trial</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1992-04-01</date><risdate>1992</risdate><volume>15</volume><issue>2</issue><spage>129</spage><epage>134</epage><pages>129-134</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>Stage III and IV epithelial ovarian cancer patients were prospectively randomized to receive eight courses of 60 mg/m2 of cisplatin plus either 75 mg/m2 of epirubicin (62 patients) or 60 mg/m2 of doxorubicin (54 patients). Clinical response rates for cisplatin/epirubicin of 42% [15% complete response (CR) and 27% partial response (PR)] and for cisplatin/doxorubicin of 55% (24% CR and 31% PR) were not statistically different (p = 0.14). The negative second look rate was 35% (10/29) for cisplatin/doxorubicin and 17% (5/30) for cisplatin/epirubicin (p = 0.12). The progression-free interval for cisplatin/epirubicin (13 months) was not statistically different (p = 0.09) from that for cisplatin/doxorubicin (19 months). The median survivals for cisplatin/epirubicin (756 days) and cisplatin/doxorubicin (739 days) were similar (p = 0.70). Cardiotoxicity was greater for the cisplatin/doxorubicin group (p = 0.0003). With similar survival and less cardiotoxicity, the cisplatin/epirubicin regimen had the more favorable therapeutic index.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>1553900</pmid><doi>10.1097/00000421-199204000-00007</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1992-04, Vol.15 (2), p.129-134 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00000421_199204000_00007 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma - drug therapy Carcinoma - pathology Chemotherapy Cisplatin - administration & dosage Double-Blind Method Doxorubicin - administration & dosage Epirubicin - administration & dosage Female Humans Medical sciences Middle Aged Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Pharmacology. Drug treatments Prospective Studies Survival Analysis |
| title | Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma : a multicenter trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T10%3A27%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20comparison%20of%20cisplatin%20plus%20epirubicin%20or%20doxorubicin%20for%20advanced%20epithelial%20ovarian%20carcinoma%20:%20a%20multicenter%20trial&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=HOMESLEY,%20H.%20D&rft.date=1992-04-01&rft.volume=15&rft.issue=2&rft.spage=129&rft.epage=134&rft.pages=129-134&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/00000421-199204000-00007&rft_dat=%3Cpubmed_cross%3E1553900%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1553900&rfr_iscdi=true |